Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21983594 | 1.00 | L3MBTL1 (0.32) | L3MBTL1EPHX2IDO1CYP3A4CYP2D6 | |
| SCHEMBL13953258 | 1.00 | L3MBTL1 (0.32) | L3MBTL1EPHX2IDO1CYP3A4CYP2D6 | |
| SCHEMBL16237425 | 0.81 | IDO1 (0.31) | IDO1CYP3A4CYP2D6CYP2B6KCNH2 | |
| SCHEMBL13932853 | 0.80 | UGT2B7 (0.32) | EPHX2 | |
| SCHEMBL13932851 | 0.80 | UGT2B7 (0.32) | EPHX2 | |
| SCHEMBL21963881 | 0.79 | L3MBTL1 (0.36) | L3MBTL1IDO1TDO2 | |
| SCHEMBL21963958 | 0.79 | L3MBTL1 (0.36) | L3MBTL1IDO1TDO2 | |
| SCHEMBL21963681 | 0.79 | L3MBTL1 (0.36) | L3MBTL1IDO1TDO2 | |
| SCHEMBL681112 | 0.78 | — | — | |
| SCHEMBL12688048 | 0.77 | ESR2 (0.36) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048227-A1 | Substituted-1-Phthalazinamines As Vr- 1 Antagonists | MERCK SHARP & DOHME CORP. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048227-A1 | Substituted-1-Phthalazinamines As Vr- 1 Antagonists | TRPV1, TRPV2, TRPV5 | L3MBTL1 3936/4885EPHX2 4566/4885IDO1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.